# Starget Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/starget-pharma

- Industry: Biotechnology
- Headquarters: Ramat Hasharon, Israel
- Website: www.stargetpharma.com/
- Total disclosed funding: $18M
- Latest round: Series A (Feb 18, 2026)
- Investors on record: 4

## About

Based in Ramat Hasharon, Israel, and founded in 2019 by by Ronen Clemson and Sigal Clemson Kushnir, Starget Pharma Ltd. operates as a biopharmaceutical firm that focuses on treating solid tumors. In February 2026, Starget Pharma Ltd. raised USD 18 million in series A funding from Louisiana Economic Development Corporation, BRF SA,Cancer Focus Fund, and Ilex Medical Ltd. also participated in the round.

The business provides a product pipeline of radiopharmaceutical compounds that are intended for delivering radioisotopes to a variety of malignant tumor tissues. The product candidate is a peptide that is chemically identical to somatostatin and is gathered into malignant tumors, where it can supply contrast chemicals for imaging or active drugs for tumor therapy.

The company plans to utilize the February 2026 funding to move its product pipeline closer to clinical trials, enhance its AI-powered in silico discovery platform, and broaden its translational and manufacturing operations across the US.

## Funding rounds

- Series A, Feb 18, 2026, $18M — Louisiana Economic Development Corporation, BRF SA, Cancer Focus Fund, Ilex Medical Ltd.

## Investors

- Louisiana Economic Development Corporation — Series A
- BRF SA — Series A
- Cancer Focus Fund (https://capitalatlas.ai/funds/cancer-focus-fund) — Series A
- Ilex Medical Ltd. — Series A